White Paper
Navigating Turbulent Waters: Learn How Life Sciences Companies Are Managing Converging Risks in an Era of Uncertainty
White Paper Summary
The life sciences sector finds itself at a critical juncture. Regulatory approvals are taking longer, talent costs are rising, and new technologies are creating both opportunities and exposures that didn’t exist a decade ago. For companies developing pharmaceuticals and medical devices, these converging challenges threaten to prevent some important innovations from ever reaching the market.
“A lot has been going on with the Food and Drug Administration,” said James Craig, Underwriting Manager, Life Science at Munich Re Specialty – North America. “There is turnover of employees, fewer resources, new guidance and less predictability from the FDA. Approvals take longer for new products or labeling changes.”
This regulatory unpredictability represents just one element of what Craig described as “rough waters” for the life sciences industry. The combination of multiple challenges arriving simultaneously has created an environment where companies must rethink their approach to risk management and seek more comprehensive partnerships with their insurance providers.
To learn more about Munich Re, please visit their website.

